These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 18398952

  • 1. Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
    Soejima M, Kawaguchi Y, Hara M, Kamatani N.
    J Rheumatol; 2008 Apr; 35(4):724. PubMed ID: 18398952
    [No Abstract] [Full Text] [Related]

  • 2. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
    Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, Yamanaka M, Yamanaka H, Kamatani N.
    Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
    [Abstract] [Full Text] [Related]

  • 3. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.
    Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y, Saito M, Yamanaka H, Saito T, Kamatani N.
    J Rheumatol; 2002 Dec; 29(12):2492-9. PubMed ID: 12465141
    [Abstract] [Full Text] [Related]

  • 4. [Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
    Taniguchi A, Kamatani N.
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():686-90. PubMed ID: 15799443
    [No Abstract] [Full Text] [Related]

  • 5. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
    Kumagai S, Komada F, Kita T, Morinobu A, Ozaki S, Ishida H, Sano H, Matsubara T, Okumura K.
    Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 8. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [Abstract] [Full Text] [Related]

  • 9. [Pharmacogenetics of disease modifying anti-rheumatic drugs].
    Taniguchi A, Urano W, Tanaka E, Akama H, Yamanaka H, Kamatani N.
    Nihon Rinsho; 2002 Dec; 60(12):2339-44. PubMed ID: 12510359
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.
    Zhang LL, Yang S, Wei W, Zhang XJ.
    Pharmacogenet Genomics; 2014 Nov; 24(11):531-8. PubMed ID: 25144752
    [Abstract] [Full Text] [Related]

  • 12. Is the cure worse than the disease?
    Sacks R.
    Aust Fam Physician; 2001 Jul; 30(7):679-80. PubMed ID: 11558203
    [No Abstract] [Full Text] [Related]

  • 13. Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis.
    van Riel PL, van Gestel AM, van de Putte LB.
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():40-2. PubMed ID: 8535648
    [Abstract] [Full Text] [Related]

  • 14. Sulfasalazine induced lichen planus in a patient of rheumatoid arthritis.
    Ghosh S, Jain VK, Chaudhuri S, Mathur SK.
    Indian J Dermatol Venereol Leprol; 2013 Nov; 79(4):541-4. PubMed ID: 23760333
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P.
    Methods Mol Biol; 2008 Nov; 448():413-35. PubMed ID: 18370240
    [Abstract] [Full Text] [Related]

  • 17. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
    O'Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, Haire C, Fernandez A.
    J Rheumatol; 2006 Feb; 33(2):213-8. PubMed ID: 16358366
    [Abstract] [Full Text] [Related]

  • 18. Use of sulfasalazine in rheumatic diseases.
    Fuchs HA.
    Bull Rheum Dis; 1997 Nov; 46(7):3-4. PubMed ID: 9366125
    [No Abstract] [Full Text] [Related]

  • 19. [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
    Jiang L, Zhao N, Ni L.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Jun; 23(3):213-7. PubMed ID: 12411093
    [Abstract] [Full Text] [Related]

  • 20. [Pharmacotherapy of patients with (early) rheumatoid arthritis].
    van Rijthoven AW.
    Ned Tijdschr Geneeskd; 2000 Mar 11; 144(11):539. PubMed ID: 10735141
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.